ライフサイエンスコーパス: fluoroquinolone

1 usceptible to levofloxacin (third-generation fluoroquinolone).

2 LL and the first to include a broad-spectrum fluoroquinolone.

3 tients, including individuals resistant to a fluoroquinolone.

4 were determined in complex with DNA and five fluoroquinolones.

5 rains also showing reduced susceptibility to fluoroquinolones.

6 bit no target-mediated cross-resistance with fluoroquinolones.

7 r issues that have been problematic for some fluoroquinolones.

8 ted by target-mediated cross resistance with fluoroquinolones.

9 determine the MIC of moxifloxacin and other fluoroquinolones.

10 solates were resistant to cephalosporins and fluoroquinolones.

11 er than double-strand cleavage, as seen with fluoroquinolones.

12 cts all isolates with acquired resistance to fluoroquinolones.

13 h and without resistance to early-generation fluoroquinolones.

14 and no target-mediated cross-resistance with fluoroquinolones.

15 al pathogens, including strains resistant to fluoroquinolones.

16 d during treatment or acquired resistance to fluoroquinolones.

17 o beta-lactam antimicrobials, macrolides, or fluoroquinolones.

18 ly receiving intravenous vs oral respiratory fluoroquinolones.

19 alytes from the groups of tetracyclines (6), fluoroquinolones (11), sulphonamides (17), nitroimidazol

20 OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients).

21 window) and prior usage of cephalosporins or fluoroquinolones (30-day window) were 7.4% and 1.3%, res

22 The most prescribed antibiotics were fluoroquinolones (35%), followed by carbapenems (20%), T

23 tibiotics families: sulfonamides (9 SDs) and fluoroquinolones (6 FQs).

24 (45 [9%] vs 18 [24%], adjusted p=0.002) and fluoroquinolones (95 [19%] vs 23 [30%], adjusted p=0.017

25 mer pool with enhanced binding qualities for fluoroquinolones, a widely used group of antibiotics in

26 To better explain known differences in fluoroquinolone action, the crystal structures of the WT

27 Fluoroquinolone activity against WT and resistant enzyme

28 e/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have bee

29 e or treated only with an earlier-generation fluoroquinolone (adjusted hazard ratio, 0.46 [95% confid

30 high probability of concurrent resistance to fluoroquinolones, aminoglycosides, or macrolides (P < .0

31 aluate the effectiveness of later-generation fluoroquinolones among patients with and without resista

32 o investigate resistance to pyrazinamide and fluoroquinolones among patients with tuberculosis.

33 he database, 843,854 individuals receiving a fluoroquinolone and 3,543,797 patients receiving a beta-

34 rugs during the intensive phase, including a fluoroquinolone and a parenteral agent, would be associa

35 ltidrug resistance with resistance to both a fluoroquinolone and a second-line injectable (XDR).

36 ant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.

37 National fluoroquinolone and cephalosporin prescribing correlated

38 The cross-link between fluoroquinolone and GyrA-G81C gyrase correlated with exc

39 eptibility to early- versus later-generation fluoroquinolones and about the role of mutation-mutation

40 have implicated an association between oral fluoroquinolones and an increased risk of uveitis.

41 to any of the tested antibiotics (including fluoroquinolones and azithromycin) or significant altera

42 older than 65 years, and primary-case use of fluoroquinolones and clindamycin exceeding total use thr

43 -sulfamethoxazole and with susceptibility to fluoroquinolones and extended-spectrum cephalosporins.

44 s these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable aminoglycosides, they wo

45 nown to cause torsades de pointes, including fluoroquinolones and intravenous haloperidol (adjusted o

46 novel approach to treating BK viremia using fluoroquinolones and leflunomide in PRTR.

47 Antibiotic resistance, particularly to fluoroquinolones and macrolides, in the major foodborne

48 Therefore, we characterized interactions of fluoroquinolones and related drugs with WT gyrase and en

49 ving known baseline DST results for at least fluoroquinolones and second-line injectable drugs, and n

50 nly 44.7% (596) had second-line DST for both fluoroquinolones and second-line injectable: 55.8% (466

51 dies have focused on the current use of oral fluoroquinolones and the risk for retinal detachment (RD

52 phalosporins, co-amoxiclav, clindamycin, and fluoroquinolones) and macrolide antibiotics; a hand hygi

53 Beta-lactam, multidrug efflux pumps, fluoroquinolone, and antibiotic inactivation ABR genes w

54 1-60 days) intermediate risk period, type of fluoroquinolone, and type of RD.

55 r types of antibiotics (rifampin, isoniazid, fluoroquinolones, and aminoglycosides) were analyzed for

56 rates and above-threshold use of macrolides, fluoroquinolones, and clindamycin.

57 cs, including beta-lactams, aminoglycosides, fluoroquinolones, and polymyxins.

58 first-line agents, second-line injectables, fluoroquinolones, and World Health Organization category

59 Fluoroquinolone antibacterials, which target DNA gyrase,

60 ocess is subject to reversible corruption by fluoroquinolones, antibacterials that form drug-enzyme-D

61 ebsiella pneumoniae increases sensitivity to fluoroquinolones; antibacterials that kill cells by inhi

62 , conferring decreased susceptibility to the fluoroquinolone antibiotic ciprofloxacin by increased ef

63 We have studied the fluoroquinolone antibiotic ciprofloxacin in an animal mo

64 Three fluoroquinolone-to-fluoroquinolone antibiotic transformations were monitore

65 (P = 0.02) or fourth-generation (P = 0.008) fluoroquinolone antibiotic was used after surgery.

66 tudy, interactions of Ciprofloxacin (CIP), a fluoroquinolone antibiotic with two sets of synthetic na

67 rane channel OmpF on the accumulation of the fluoroquinolone antibiotic, norfloxacin, in proteoliposo

68 s work, we report measurements on a range of fluoroquinolone antibiotics and find that their pH depen

69 with small-molecule inhibitor interactions (fluoroquinolone antibiotics and the newly reported antag

70 The immunosuppressant azathioprine, the fluoroquinolone antibiotics and vemurafenib-a BRAF inhib

71 Quinolone and fluoroquinolone antibiotics are potent, broad-spectrum a

72 , the immunosuppressant azathioprine and the fluoroquinolone antibiotics ciprofloxacin and ofloxacin

73 enotypic resistance markers of macrolide and fluoroquinolone antibiotics in 23S ribosomal RNA, gyrA,

74 cin, representative of an important class of fluoroquinolone antibiotics, has been considered to be o

75 diated change in bacterial susceptibility to fluoroquinolone antibiotics.

76 ng and resistance to rifampin, isoniazid and fluoroquinolone antibiotics.

77 Our results suggest that fluoroquinolones are a risk factor for MRSA acquisition.

78 Fluoroquinolones are broad-spectrum antibacterials that

79 Fluoroquinolones are effective for clinical outcomes but

80 Pyrazinamide and fluoroquinolones are essential antituberculosis drugs in

81 Moxifloxacin and other fluoroquinolones are important therapeutic agents for th

82 Fluoroquinolones are one of the most commonly prescribed

83 Fluoroquinolones are the core drugs for the management o

84 Fluoroquinolones are the most commonly prescribed antibi

85 Since antimicrobials, specifically fluoroquinolones, are one of the only routinely used con

86 hibition of DNA gyrase was distinct from the fluoroquinolones, as shown by their ability to inhibit t

87 Fluoroquinolone-based regimens, once the mainstay of man

88 Several other C7 aryl fluoroquinolones behaved in a similar manner with partic

89 g most of those resistant to cephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors,

90 were generally susceptible to penicillin and fluoroquinolones but not to erythromycin.

91 rate constants for transformation of the six fluoroquinolones by direct photolysis at 253.7 nm were d

92 have been crystallized and found to have the fluoroquinolone C-7 ring system facing the GyrB/ParE sub

93 tes were then assessed for susceptibility to fluoroquinolone, cephalosporin, and aminoglycoside antib

94 A follow-up of antibiotics (tetracyclines, fluoroquinolones, cephalosporins, penicillins and amphen

95 a DNA-embedded azathioprine surrogate), the fluoroquinolones ciprofloxacin and ofloxacin and vemuraf

96 inhibitor classes, including the widely used fluoroquinolone class.

97 rvention limiting the use of 4C antibiotics (fluoroquinolones, clindamycin, co-amoxiclav, and cephalo

98 rtation pressures, bed occupancy, and use of fluoroquinolones, co-amoxiclav, and third-generation cep

99 od showed a small increase in the HR for the fluoroquinolone cohort (1.11; 95% CI, 1.05-1.17; P < .00

100 confidence interval [CI], 0.01-0.06) of the fluoroquinolone cohort, 0.02% (95% CI, 0.01-0.03) of the

101 cription in 0.01% (95% CI, 0.00-0.03) of the fluoroquinolone cohort, 0.02% (95% CI, 0.01-0.04) of the

102 The use of fluoroquinolone-containing (moxifloxacin and gatifloxaci

103 The disappointing recent failure of fluoroquinolone-containing regimens to shorten the durat

104 r in fecal samples from people living in the fluoroquinolone-contaminated villages.

105 e intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a reduction in contacts

106 Compared with nonusers of fluoroquinolones, current first-time users of moxifloxac

107 We evaluated two quinolone disks and five fluoroquinolone disks for their ability to act as a surr

108 We evaluated 16 quinolone/fluoroquinolone disks for their ability to detect low-le

109 ely, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant

110 le levels of resistance to fourth-generation fluoroquinolones documented in all survey sites is an en

111 rapidly and accurately predict resistance to fluoroquinolone drugs and especially later-generation ag

112 NAPCR1 strains are resistant to fluoroquinolones due to a mutation in gyrA, and they pos

113 years), 663 patients with RD were exposed to fluoroquinolones during the observation period, correspo

114 Exposure to fluoroquinolones during the risk period (1-10 days) comp

115 Fluoroquinolones (e.g., ciprofloxacin) have become a mai

116 n, which can be corrected by exposure to the fluoroquinolone enoxacin.

117 notic pathogen Pasteurella multocida and the fluoroquinolone enrofloxacin.

118 structural data revealed few differences in fluoroquinolone-enzyme contacts from drugs that have ver

119 By dissecting fluoroquinolone-enzyme interactions, we determined that

120 Cost-effectiveness was greatest using a fluoroquinolone/ethambutol combination regimen.

121 loxacin sensitive organism and no subsequent fluoroquinolone exposure.

122 tigation and could inform the selection of a fluoroquinolone for treatment.

123 Among hospitalized patients who received fluoroquinolones for CAP, there was no association betwe

124 lth ministries in South Asia still recommend fluoroquinolones for enteric fever.

125 Fluoroquinolones form drug-topoisomerase-DNA complexes t

126 genes responsible for resistance to INH, the fluoroquinolone (FQ) drugs, amikacin (AMK), and kanamyci

127 acin (ERFX) is a synthetic antibiotic of the fluoroquinolone (FQ) family, which is commonly administe

128 gnostics that rapidly and accurately predict fluoroquinolone (FQ) resistance promise to improve treat

129 Early fluoroquinolone (FQ) use was defined as receiving >/=5 d

130 o assess risk factors for the development of fluoroquinolone (FQ)-resistant Escherichia coli gastroin

131 Fluoroquinolones (FQ) are powerful broad-spectrum antibi

132 de the simultaneous electroanalysis of three fluoroquinolones (FQ) as emerging contaminants (ECs).

133 Fluoroquinolone (FQN) therapy of latent tuberculosis inf

134 R) to second-line injectable drugs (SLIs) or fluoroquinolones (FQs) and mortality among tuberculosis

135 An association between use of oral fluoroquinolones (FQs) and retinal detachment remains co

136 Fluoroquinolones (FQs) are among the drugs of choice for

137 Fluoroquinolones (FQs) are broad-spectrum antibiotics re

138 Three fluoroquinolones (FQs) are commonly prescribed as part o

139 Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the p

140 osis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables.

141 uggesting that removal of a later-generation fluoroquinolone from a treatment regimen because of demo

142 elapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fe

143 ept for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was associated with equival

144 frequent hospital admissions, greater use of fluoroquinolones, glycopeptides, cephalosporins and othe

145 isolates were high for amikacin (59.2%) and fluoroquinolones (>97%).

146 f an associated magnesium ion, which bridges fluoroquinolone-gyrase interactions.

147 participants treated with a later-generation fluoroquinolone had half the risk of mortality compared

148 Patients who received oral fluoroquinolones had lower unadjusted mortality (1.4% vs

149 Fluoroquinolones have equivalent oral and intravenous bi

150 Fluoroquinolones have high resistance rates among MDR ur

151 mum inhibitory concentrations (MICs) against fluoroquinolones have risen significantly since 2005 and

152 ith several factors, including resistance to fluoroquinolones, high virulence gene content, the posse

153 NAP1V is not resistant to fluoroquinolones, however.

154 idence interval [CI], 1.30-4.00; P = 0.004), fluoroquinolones (HR, 2.29, 95% CI, 1.32-3.98; P = 0.003

155 ded-spectrum cephalosporins, macrolides, and fluoroquinolones in 1102 resistant and susceptible clini

156 pression of extensive and unregulated use of fluoroquinolones in some parts of Asia, the negligible l

157 ate biopsy are attributable to resistance to fluoroquinolones in the USA.

158 Sensitivity to fluoroquinolones included 22 of 52 (42%) to levofloxacin

159 Fluoroquinolone-induced peripheral neuropathies and tend

160 tance to third-generation cephalosporins and fluoroquinolones is currently uncommon but has been iden

161 ideally evaluate for resistance to rifampin, fluoroquinolones, isoniazid, and pyrazinamide and enable

162 of unrelated substrates, such as hydrophilic fluoroquinolones, leading to a multidrug-resistance phen

163 d with high abundances of qnr, whereas lower fluoroquinolone levels in well water and soil did not.

164 n particular, the current large-scale use of fluoroquinolones, macrolides, and third-generation cepha

165 studies suggest that use of later-generation fluoroquinolones may reduce mortality risk and improve t

166 County, Minnesota, who were prescribed oral fluoroquinolone medications from January 1, 2003, to Jun

167 in Salmonella when the direct measurement of fluoroquinolone MICs is not feasible [corrected].

168 nstrated resistance to an earlier-generation fluoroquinolone might increase mortality risk.

169 lactam plus macrolide combination therapy or fluoroquinolone monotherapy initiated within 4 to 8 hour

170 populations of 2068 to 24,780) reported that fluoroquinolone monotherapy was associated with relative

171 with a beta-lactam-macrolide combination or fluoroquinolone monotherapy with regard to 90-day mortal

172 eta-lactam-macrolide combination therapy, or fluoroquinolone monotherapy.

173 at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin.

174 ess the association between later-generation fluoroquinolone (moxifloxacin or levofloxacin) use and p

175 received moxifloxacin; all had pretreatment fluoroquinolone mutations detected.

176 ation 80Ala and 90Gly represented 57% of all fluoroquinolone mutations identified from MDR-TB patient

177 Multivariable analysis retained fluoroquinolones (odds ratio, 2.17; 95% confidence inter

178 2.3, whereas for second-line injectables and fluoroquinolones, odds ranged from 2.4 to 4.6.

179 ce and treatment regimen, including use of a fluoroquinolone, on clinical outcomes.

180 the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapi

181 created including every new user of an oral fluoroquinolone or beta-lactam antibiotic prescription w

182 ith participants either not treated with any fluoroquinolone or treated only with an earlier-generati

183 tion of mutations associated with high-level fluoroquinolone (OR, 3.99 [95% CI, 1.10 to 14.40]) and k

184 olates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sang

185 INTERPRETATION: Restricting fluoroquinolone prescribing appears to explain the decli

186 The hazard of a uveitis diagnosis after a fluoroquinolone prescription compared with a beta-lactam

187 tion efficiencies were inflated by 2-8% when fluoroquinolone products were not considered; moreover,

188 log(days)], 0.62; 95% CI, .44-.89; P = .009; fluoroquinolones: profile penalized-likelihood OR [log(d

189 ents who underwent susceptibility testing to fluoroquinolones, proportions of resistance ranged from

190 e to multiple protomers, including the known fluoroquinolone protomers and the new finding of cephalo

191 U, necessitates treatment with macrolides or fluoroquinolones rather than doxycycline, the preferred

192 IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topology by creating tran

193 the activity of early- and later-generation fluoroquinolones requires further investigation and coul

194 nce of S Typhi exhibiting resistance against fluoroquinolones, requiring the trial to be stopped.

195 monly prescribed classes of antibiotics, but fluoroquinolone resistance (FQR) is widespread and incre

196 ERPRETATION: The rapid expansion of ESBL and fluoroquinolone resistance among common Gram-negative pa

197 ression model yielded the combined traits of fluoroquinolone resistance and gene encoding the type II

198 We found that gyrB mutations contribute to fluoroquinolone resistance both individually and through

199 We describe here the misidentification of fluoroquinolone resistance by the GenoType MTBDRsl (MTBD

200 ip between type three secretion genotype and fluoroquinolone resistance for P. aeruginosa strains iso

201 to broth microdilution for the detection of fluoroquinolone resistance in 135 typhoidal and nontypho

202 ct as a surrogate agent for the detection of fluoroquinolone resistance in a collection of 136 S. ent

203 Detection of fluoroquinolone resistance in Salmonella enterica has be

204 Fluoroquinolone resistance in Salmonella is mostly due t

205 ensive surrogate laboratory method to detect fluoroquinolone resistance in Salmonella when the direct

206 Fluoroquinolone resistance is a serious and increasingly

207 s to extensively resistant disease; however, fluoroquinolone resistance is emerging and new ways to b

208 However, fluoroquinolone resistance is increasing in Salmonella d

209 ent, but its efficacy should be evaluated as fluoroquinolone resistance is rapidly increasing.

210 ases failing moxifloxacin were sequenced for fluoroquinolone resistance mutations.

211 s may improve the accuracy of predicting the fluoroquinolone resistance phenotype.

212 The results indicate that fluoroquinolone resistance reached to 35.4% in C. jejuni

213 h extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose significantly after 2003

214 ion, this clone evolved rapidly and acquired fluoroquinolone resistance through precise stepwise muta

215 Fluoroquinolone resistance was more common among E. coli

216 to the detection of phenotypic rifampin and fluoroquinolone resistance with negligible increases in

217 ineage of ST131 strains was characterized by fluoroquinolone resistance, and a distinct virulence fac

218 ns in the gyr genes are known to confer most fluoroquinolone resistance, but knowledge about the effe

219 In areas of high fluoroquinolone resistance, ciprofloxacin can be used em

220 esidues rationalizing why QPT-1 can overcome fluoroquinolone resistance.

221 nt was infected with a DLST having genotypic fluoroquinolone resistance.

222 plicated cystitis and 42.6% Escherichia coli fluoroquinolone resistance.

223 Furthermore, fluoroquinolone-resistance in K. pneumoniae clinical iso

224 While all fluoroquinolone resistant (FQ(R)) C. coli isolates exami

225 nt minimum inhibitory concentrations against fluoroquinolone resistant MRSA and other Gram-positive b

226 Fluoroquinolone-resistant (57% vs 34%, 16%; p < 0.0001)

227 ncidence of C difficile infections caused by fluoroquinolone-resistant and fluoroquinolone-susceptibl

228 thromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria g

229 Fluoroquinolone-resistant clinical and rectal E. coli is

230 Fluoroquinolone-resistant clinical isolates of bacteria

231 Presence of fluoroquinolone-resistant colonizing E. coli was the mos

232 cology compared to nononcology locations for fluoroquinolone-resistant E. coli (rate ratio, 7.37; 95%

233 fore the biopsy and cultured selectively for fluoroquinolone-resistant gram-negative bacilli.

234 fficile decline was driven by elimination of fluoroquinolone-resistant isolates (approximately 67% of

235 C difficile infections caused by fluoroquinolone-resistant isolates declined in four dist

236 The regions of phylogenies containing fluoroquinolone-resistant isolates were short-branched a

237 rred secondary (transmitted) cases caused by fluoroquinolone-resistant isolates with or without hospi

238 e potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae,

239 wn by their ability to inhibit the growth of fluoroquinolone-resistant Mtb.

240 monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant multidrug resistance, second-l

241 plex by N. gonorrhoeae gyrase increased in a fluoroquinolone-resistant mutant enzyme.

242 ld resistance to AZD0914, was present in the fluoroquinolone-resistant mutant, the potency of ciprofl

243 conflicting regarding the importance of the fluoroquinolone-resistant North American pulsed-field ge

244 Rectal colonization with fluoroquinolone-resistant organisms (98% E. coli) was de

245 can identify nearly all patients at risk for fluoroquinolone-resistant post-TPB infection.

246 ng E. coli population is the source for most fluoroquinolone-resistant post-TPB infections, regardles

247 Fluoroquinolone-resistant typhoid is increasing.

248 Post-TPB infection was more common among fluoroquinolone-resistant-colonized subjects than noncol

249 The importance of fluoroquinolone restriction over infection control was s

250 Post-fluoroquinolone retinal detachment repair rates were sim

251 ovide an update of phase 3 trials of various fluoroquinolones (RIFAQUIN, NIRT, OFLOTUB, and REMoxTB).

252 erapy vs 23% [386 of 1,680] with beta-lactam/fluoroquinolone; risk ratio, 0.83; 95% CI, 0.67-1.03; p

253 of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant were determined in com

254 Our results suggest that fluoroquinolones should no longer be used for treatment

255 Use of later-generation fluoroquinolones significantly reduced patient mortality

256 ants for cationic, zwitterionic, and anionic fluoroquinolone species.

257 Although fluoroquinolones stabilize double-stranded DNA breaks, t

258 am strategy to the beta-lactam-macrolide and fluoroquinolone strategies with respect to 90-day mortal

259 days (interquartile range, 0 to 4) with the fluoroquinolone strategy and 4 days (interquartile range

260 crolide strategy periods, and 888 during the fluoroquinolone strategy periods, with rates of adherenc

261 entage points (90% CI, -2.8 to 1.9) with the fluoroquinolone strategy than with the beta-lactam strat

262 velop resistance to DNM are re-sensitized to fluoroquinolones, suggesting that resistance that emerge

263 Genotype (multilocus sequence type) and fluoroquinolone susceptibility were determined from whol

264 f exoU in laboratory isolates did not affect fluoroquinolone susceptibility.

265 no change in either group of cases caused by fluoroquinolone-susceptible isolates (p>0.2).

266 ions caused by fluoroquinolone-resistant and fluoroquinolone-susceptible isolates was estimated with

267 cidence rate ratio 0.52, 95% CI 0.48-0.56 vs fluoroquinolone-susceptible isolates: 1.02, 0.97-1.08).

268 a narrow range of alleles of gyrA and parC (fluoroquinolone target genes).

269 ein synthesis such as macrolides, along with fluoroquinolones that inhibit DNA replication, have been

270 y C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated qu

271 on prevalence densities were associated with fluoroquinolone, third-generation cephalosporin, macroli

272 Three fluoroquinolone-to-fluoroquinolone antibiotic transforma

273 colonization and/or recent cephalosporin or fluoroquinolone usage.

274 a uveitis-associated systemic illness after fluoroquinolone use (HR range, 1.46-1.96; 95% CI, 1.42-2

275 e literature, suggest an association between fluoroquinolone use and the risk for RD.

276 this study shows an association between oral fluoroquinolone use and the risk for uveitis-associated

277 a do not support an association between oral fluoroquinolone use and uveitis.

278 Fluoroquinolone use is associated with increased risk of

279 Current oral fluoroquinolone use was associated with an increased ris

280 Oral fluoroquinolone use was assumed to start on the day the

281 Vancomycin and fluoroquinolone use was decreased.

282 Oral fluoroquinolone use was not associated with an increased

283 Given the widespread fluoroquinolone use, investigation of this association i

284 ce, such as antibiotic stewardship to reduce fluoroquinolone use, might reduce CDI morbidity.

285 TCFs should also be based on optimization of fluoroquinolone use.

286 and there has been no history of intervening fluoroquinolone use.

287 gs (including a second-line injectable and a fluoroquinolone) used for at least 6 months post culture

288 to be equally or more potent than the parent fluoroquinolones using an Escherichia coli-based assay.

289 The rate of endophthalmitis was lower if a fluoroquinolone was used after surgery.

290 the pncA gene, and susceptibility testing to fluoroquinolones was conducted using the MGIT system.

291 m beta-lactams and/or aminoglycosides and/or fluoroquinolones was started.

292 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were active against 94% and 88% of isol

293 Fluoroquinolones were detected by MS/MS in well water an

294 Recent and past use of fluoroquinolones were not associated with a higher risk

295 B were treated for greater than 14 days, and fluoroquinolones were the most commonly used empiric ant

296 acto monotherapy with a critical drug class (fluoroquinolones), whereas the latter could exclude larg

297 xacin, one of the most frequently prescribed fluoroquinolone, with high affinity (KD=0.1-56.9 nM).

298 e 10-day period after the dispensing of oral fluoroquinolones, with an adjusted odds ratio of 1.46 (9

299 rest was current use, defined as exposure to fluoroquinolones within 10 days immediately before RD su

300 ound to be associated with susceptibility to fluoroquinolones, yet it leads to absent hybridization o